Tolero Licenses Btk Drugs from MannKind for $130M
A new license agreement between Tolero Pharmaceuticals Inc., of Salt Lake City, and MannKind Corp., of Valencia, Calif., will grant Tolero exclusive worldwide rights to some of MannKind's Bruton's tyrosine kinase (Btk) compounds, which have potential for hematological malignancies and inflammatory disease.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter